Table 1.
MDM2-inhibitors.
| Target | Drug | Phase | Sarcoma | Combination | NCT | Published |
|---|---|---|---|---|---|---|
| MDM2 | Navtemadlin (AMG-232 [KRT-232 | 1B | Only | Radiotherapy | NCT03217266 | |
| MDM2 | Navtemadlin | 1/2 | NO | TL-895 | NCT02825836 | |
| MDM2 | Navtemadlin | 2 | No | No | NCT03662126 | |
| MDM2 | APG-115 | 2 | No | nO | NCT03781986 | |
| MDM2 | Brigimadlin (BI 907828 | 2 | DDLPS | No | NCT06058793 | |
| MDM2 | Brigimadlin BI 907828 | 2 | DDLPS | ADRYAMICIN | NCT05218499 | |
| MDM2 | Brigimadlin BI 907828 | 1 | included | Ezabenlimab | NCT03964233 | |
| MDM2 | Brigimadlin BI 907828 | 1 | Included | No | NCT03449381 | LoRusso [119,120] |
| MDM2 | CGM097 | 1B | included | NO | NCT01760525 | |
| MDM2/MDMX | Idasanutlin | 1B | RMS | Selinexor | NCT05952687 | |
| MDM2/MDMX | Idasanutlin | 1/2 | No | Atezolizumaband Cobimetinib | NCT03566485 |
DDLPS: dedifferentiated liposarcoma, RMS: rhabdomyosarcoma.